YOLFTbeta
SN

Syntara Ltd

SNT · AU · Healthcare / Drug Manufacturers - Specialty & Generic

0.014AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.014
Open0.0145
Day Range0.013 – 0.0145
52-Week Range0.019 – 0.036
Volume1.66M
Market Cap39.29M
P/E (TTM)0.00
Forward P/E20.45
EPS-0.01
Dividend Yield0.00%
Beta0.24
50-Day Avg0.0251
200-Day Avg0.0281

About

Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Gary Jonathan Phillips BPharm, MBA
  • Employees21
  • Headquarters20A Rodborough Road, Frenchs Forest, NSW, Australia, 2086, Australia
  • Websitehttps://syntaratx.com.au

Leadership

  • Mr. Gary Jonathan Phillips BPharm, MBACEO, MD & Director · b. 1961
  • Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D.Head of Drug Discovery · b. 1964
  • Ms. Kristen Morgan B.Sc., MMedSc, PGDipBusAdminHead of Medical & Regulatory Affairs - Alliance Management · b. 1972
  • Dr. Jana BaskarChief Medical Officer
  • Mr. Timothy Luscombe B.Com., C.A.CFO & Company Secretary
  • Mr. Cameron David Billingsley BA, LLB (Hons.)General Counsel · b. 1977
  • Dr. Dieter HamprechtHead of Chemistry

Financials

Income Statement

Currency: AUD2003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue41.44K-5008.00K2.36M527.00K828.00K1.17M1.20M1.47M5.04M57.74M14.34M13.78M49.41M5.68M7.03M23.63M7.43M5.76M5.76M5.43M7.30M-
Growth (%)---+1500.00%+29362.50%-77.64%+57.12%+41.30%+2.74%+21.96%+243.52%+1046.56%-75.17%-3.91%+258.71%-88.51%+23.80%+236.22%-68.57%-22.37%0.00%-5.85%+34.45%-
Cost of Revenue---2.00K49.00K129.00K153.00K307.00K342.00K522.00K1.14M1.86M15.48M15.45M1.77M15.92M16.12M15.43M9.95M2.71M8.30M-223.00K146.00K
Gross Profit41.44K-5006.00K2.31M398.00K872.00K863.00K860.00K944.00K2.10M3.18M-1.15M-1.67M47.27M-10.24M-9.09M7.21M7.43M3.06M3.06M--223.00K-146.00K
Gross Margin100.00%-100.00%75.00%97.92%75.52%105.31%73.76%71.55%64.39%41.62%5.50%-8.02%-12.15%95.67%-180.50%-129.36%30.53%100.00%53.06%53.06%--3.06%-
Operating Expense3.03M-13.73M24.11M32.69M30.81M50.86M49.26M45.71M48.21M43.17M-11.77M21.05M20.62M30.34M14.26M11.79M11.61M27.34M22.89M21.75M-21.93M16.21M
Operating Income-2.99M-8.72M-13.73M-24.10M-30.38M-30.41M-49.99M-48.40M-44.85M-47.27M-41.08M14.94M-22.20M-22.29M16.93M-24.50M-20.88M-4.40M-19.91M-19.83M-18.69M-14.06M-22.15M-16.35M
Operating Margin-7204.29%--2746425.60%-301262.50%-1288.80%-5770.40%-6037.56%-4136.58%-3731.28%-3224.42%-815.65%25.88%-154.87%-161.84%34.27%-431.71%-297.07%-18.63%-268.10%-344.04%-324.22%-259.06%-303.49%-
EBITDA-2.73M-8.23M-13.11M-23.31M-29.44M-29.39M-46.97M-43.37M-39.82M-42.45M-26.92M18.35M-19.17M-19.23M-14.66M-21.89M-17.20M-1.25M551.00K-17.99M-9.29M-13.05M-12.00M-16.21M
EBITDA Margin-6587.19%--2621199.40%-291362.50%-1248.96%-5576.09%-5672.71%-3707.01%-3313.14%-2895.63%-534.61%31.78%-133.75%-139.63%-29.68%-385.57%-244.78%-5.29%7.42%-311.99%-161.13%-240.38%-164.48%-
Net Income-1.47M-6.00M-10.23M-17.73M-24.18M-20.44M-35.17M-46.34M-45.76M-38.64M-43.54M-51.82M18.47M-16.46M-18.35M6.43M-20.06M-13.94M-2.97M-1.94M-11.36M-15.14M-7.92M-9.00M
Net Income Margin-3541.88%--2046471.40%-221662.50%-1025.84%-3878.56%-4247.71%-3961.11%-3806.82%-2636.02%-864.52%-89.74%128.82%-119.51%-37.13%113.25%-285.44%-59.02%-39.99%-33.58%-197.05%-278.96%-108.51%-
R&D1.79M6.05M9.15M16.98M23.84M20.00M29.31M35.14M34.63M29.22M23.86M17.70M----8.66M6.34M4.77M7.22M8.71M--7.38M
R&D as % of Total Revenue4318.82%-1830904.80%212225.00%1011.46%3794.31%3539.61%3003.42%2881.20%1993.32%473.83%30.66%----123.27%26.84%64.19%125.31%151.14%---
Interest Expense------122.00K854.00K859.00K768.00K2.94M7.30M--623.00K563.00K238.00K-369.00K223.00K223.00K386.00K30.00K-
Interest Expense % of Total Revenue------14.73%72.99%71.46%52.39%58.48%12.65%--1.26%9.92%3.39%-4.97%3.87%3.87%7.11%0.41%-

Balance Sheet

Currency: AUD2003-06-302004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets29.79M28.26M37.94M104.27M82.65M125.05M164.00M140.77M94.57M131.70M112.28M66.75M82.56M65.65M45.43M50.10M52.67M35.42M33.59M25.19M24.03M10.38M21.44M19.14M
Total Liabilities604.50K1.48M2.37M5.38M6.09M5.93M26.31M25.75M23.74M21.90M44.38M48.68M46.24M44.73M41.91M38.98M37.85M33.98M30.75M14.38M14.47M5.70M5.42M2.92M
Total Equity29.19M26.78M35.57M98.89M76.56M119.12M137.69M115.02M70.83M109.80M67.89M18.07M36.32M20.93M3.52M11.12M14.81M1.43M2.85M10.80M9.56M4.68M16.02M16.21M
Cash26.68M25.22M934.78K97.84M76.18M111.84M124.99M85.79M44.34M81.47M63.94M34.18M54.14M39.21M21.50M31.07M31.12M14.76M18.71M8.94M9.23M3.52M15.08M13.56M
Total Debt-----13.88M13.88M13.53M13.16M12.66M12.15M11.57M10.89M10.12M9.25M8.27M7.17M8.15M6.32M4.29M2.04M-84.00K-
Net Debt-26.68M-25.22M-934.78K-97.84M-76.18M-97.97M-111.12M-72.26M-31.18M-68.81M-51.79M-22.61M-43.24M-29.09M-12.25M-22.80M-23.95M-6.61M-12.39M-4.65M-7.19M--14.99M-13.56M

Cash Flow

Currency: AUD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-4.65M-9.27M-13.78M-20.70M-18.85M-26.47M-39.68M-37.37M-38.14M-35.38M-28.13M21.78M-11.99M-15.26M12.21M-19.80M-13.28M3.07M-16.30M-7.28M--11.12M-9.78M
Investing Cash Flow-405.59K-1.57M-1.80M-1.32M-5.06M-11.54M1.14M-2.88M-169.00K-529.00K-313.00K-264.00K-1.38M-723.00K-884.00K-981.00K-574.00K-644.00K-306.00K-131.00K-4.18M-2.00K
Financing Cash Flow22.89M19.02M80.03M363.00K59.57M51.12M-772.00K-758.00K75.43M18.37M-1.36M-1.79M-1.71M-1.72M-1.75M20.83M-2.50M1.52M6.63M6.98M7.20M18.46M8.26M
Capital Expenditure360.09K1.57M1.80M1.37M5.06M13.05M2.98M1.41M279.00K530.00K347.00K266.00K1.38M723.00K840.00K981.00K574.00K647.00K307.00K138.00K7.00K02.00K
Free Cash Flow-5.01M-10.85M-15.58M-22.07M-23.91M-39.52M-42.66M-38.78M-38.42M-35.91M-28.48M21.51M-13.37M-15.98M11.37M-20.78M-13.86M2.42M-16.61M-7.42M-14.49M-11.12M-9.78M
Dividends Paid-----------------2.31M2.38M2.25M---
FCF to OCF107.74%116.97%113.10%106.64%126.84%149.29%107.50%103.78%100.73%101.50%101.23%98.78%111.54%104.74%93.12%104.96%104.32%78.94%101.88%101.90%-100.00%100.02%
Dividend Paid to FCF-----------------95.05%-14.32%-30.30%---

Earnings

Report DateJan 28, 2009Jan 25, 2011Apr 13, 2011Jul 20, 2011Oct 12, 2011Jan 24, 2012Jan 23, 2013Aug 20, 2014Oct 15, 2014Feb 29, 2016Oct 12, 2016Jan 30, 2017Apr 19, 2017Aug 10, 2017Oct 18, 2017Jan 28, 2018Apr 30, 2018Aug 16, 2018Oct 26, 2018Feb 14, 2019Apr 29, 2019Jul 26, 2019Oct 30, 2019Feb 13, 2020May 1, 2020Aug 12, 2020Oct 29, 2020Jan 28, 2021Jun 4, 2021Jul 28, 2021Oct 27, 2021Jan 30, 2022Apr 28, 2022Aug 30, 2022Oct 30, 2022Jan 30, 2023Jul 20, 2023Oct 30, 2023Jan 30, 2024Apr 29, 2024Aug 30, 2024Nov 29, 2024Feb 26, 2025May 30, 2025Aug 28, 2025Nov 28, 2025Apr 28, 2026
EPS Estimate-0.03-0.05-0.06-0.06-0.04-0.04-0.040.00-0.000.000.000.000.000.000.00-0.00-0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
EPS Actual-0.05-0.05-0.05-0.05-0.04-0.04-0.040.00-0.030.00-0.01-0.03-0.01-0.020.070.020.030.00-0.02-0.03-0.02-0.020.00-0.030.00-0.010.000.000.00-0.010.00-0.020.000.010.00-0.010.000.000.000.000.000.000.000.000.000.000.00
Surprise-66.67%0.00%16.67%16.67%0.00%0.00%0.00%---------15100.00%100.00%-----------------------------
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours----------------------------------------

Key Statistics & Ratios

Market Cap39.29M
Enterprise Value32.16M
Trailing P/E0.00
Forward P/E20.45
PEG Ratio2.49
Price / Sales5.67
Price / Book2.91
EPS-0.01
Book Value0.008
Revenue (TTM)6.93M
Gross Profit (TTM)-450.00K
EBITDA-9.53M
Profit Margin-129.78%
Operating Margin-95.99%
Return on Equity-59.65%
Return on Assets-29.81%
Shares Outstanding1.96B
Shares Float1.53B
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%